A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Stopped Business decision, insufficient enrollment, no safety or efficacy concerns.

Conditions

• Lymphoma, Non-Hodgkin

Interventions

• DRUG: TAK-659
• DRUG: Bendamustine
• DRUG: Rituximab
• DRUG: Gemcitabine
• DRUG: Lenalidomide
• DRUG: Ibrutinib

Sponsor

Millennium Pharmaceuticals, Inc.